Natalie joined Abingworth as a Venture Partner in August 2022. Prior to this Natalie was CEO of Adaptate Biotherapeutics Ltd an Abingworth founded company, focused on developing therapeutic antibodies to drug targets to modulate the activity of gamma delta T cells. Previously, Natalie was CSO of GammaDelta Therapeutics Ltd. (also founded by Abingworth) which targeted gamma delta T-cell therapies for use in immunotherapy and was one of the founding team at the Cell and Gene Therapy Catapult serving as its Chief Clinical Officer advising academics and small companies developing advanced therapies. Natalie’s prior experience also includes 16 years at Pfizer, leading development activities across various therapeutic areas, including cell-based therapies in the Regenerative Medicine Unit. Natalie has a first-class degree in Natural Sciences from the University of Cambridge and a Ph.D. from University College, London.
